Prime Movers Lab raises $245M fund aimed at investing in early stage science startups

Dakin Sloss, Prime Movers Lab general partner, joined Yahoo Finance to discuss the company's new $245 million fund to invest in early stage science startups.

Video Transcript

[MUSIC PLAYING]

ADAM SHAPIRO: Roughly 30 minutes to the closing bell and the indices are in the green. We talk P/E sometimes, let's talk VC right now. And we invite into the stream two important people. First, Dakin Sloss, the Prime Movers Lab general partner and founder, and Julia La Roche, who is a correspondent here at Yahoo Finance.

Dakin, I just want to ask you real quick. You just raised $245 million for a fund that's going to look for scientific startups. For someone like me, who might be interested in getting in on this kind of thing, what kind of startups are you looking at when you say scientific?

DAKIN SLOSS: First off, thank you so much for having me on. I really appreciate the opportunity. So what we mean by a scientific startup is a company where the core value proposition is in the intellectual property, some sort of scientific breakthrough. Maybe this is energy, transportation, manufacturing, biotech. These kinds of companies, where what they've invented is a fundamental change in the market that they're going after.

JULIA LA ROCHE: Dakin, I just want to congratulate you. This is your second fund. Adam was just mentioning, 245 million raised here and some big name backers. I know Bill Ackman backed the first fund. You have Dmitry Balyasny, Joe Lonsdale, and just a handful of very well-known investors.

So you're pretty young, I want to kind of hear from you, how do you get these investors on board with what you're doing, especially at a young age?

DAKIN SLOSS: Well, yeah, thank you. I think, first off, it has to do with the amazing entrepreneurs that we have. So in our first fund, we've backed a lot of really phenomenal companies, like Momentus, which has already announced that it's going public in a SPAC merger. Upward Farms, Covaxx, Heliogen, these are companies that are literally transforming billions of lives.

And so I think it really appeals to investors for two reasons. One is we're producing fantastic returns. Our first fund is on track to be one of the best performing funds of 2018. But also, the companies we're investing in are feeding the planet, making it possible for space infrastructure to happen for the first time, providing billions of doses of coronaviruses vaccines to help end this pandemic.

And I think people like to put their money in someplace that's actually going to have a meaningful difference for the quality of human life.